Abstract / Summary
To explore refill adherence to prescribed treatment for chronic heart failure (CHF) and/or chronic obstructive pulmonary disease (COPD), during and after a remote person-centred care (PCC) intervention. Post hoc analysis of a randomised controlled trial cohort. We used data from the PROTECT (Person-Centred Care at Distance) randomised controlled trial in Swedish primary care, which were linked to data from the Swedish Prescribed Drug Register. A total of 222 participants from nine primary care centres were enrolled in PROTECT. This study included participants with dispensed medications for CHF and/or COPD, excluding those with multidose dispensing (intervention n=50; control n=49, 42% women, mean age 69 years). PROTECT evaluated a PCC intervention using a digital platform and structured telephone support in addition to usual care versus usual care alone. Refill adherence was compared between groups, defining appropriate medication supply as ≥80% of days covered over 2 years. We also examined associations between refill adherence and number of long-term conditions and medications. Refill adherence did not differ significantly between groups. A higher number of long-term conditions was associated with lower odds of refill adherence (adjusted OR (aOR) per additional condition: 0.71; 95% CI 0.50 to 0.97; p=0.041), as were more long-term medications (aOR per additional medication class: 0.84; 95% CI 0.71 to 0.98; p=0.029). The PROTECT intervention did not improve refill adherence, suggesting that future person-centred interventions may require more structured medication-management focus. Increasing numbers of long-term conditions and medications were both associated with lower refill adherence. NCT03183817.
Primary Source
BMJ open
Ask Prognia AI
Have questions about this randomised trial?
Prognia AI can search this source alongside 35M+ PubMed papers and current ESC, AHA, NICE, and ADA guidelines to give you a fully cited clinical answer.
Related Clinical Guidelines
Related Blog Posts
ESC 2023 Heart Failure Guidelines: What Every Cardiologist Needs to Know
The 2023 focused update to the ESC Heart Failure Guidelines introduced key changes to SGLT2 inhibitor recommendations, HFmrEF management, and device therapy thresholds. Here is a practical summary.
CHADS₂-VASc in Practice: When to Start Anticoagulation in AF
A practical walkthrough of the CHADS₂-VASc scoring system, its ESC guideline thresholds, and how to use it alongside HAS-BLED to counsel patients with atrial fibrillation.